- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01050296
Molekylær analyse af faste tumorer (MAST)
This study will prospectively characterize the molecular, cellular and genetic properties of primary and metastatic neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma family of tumors, soft tissue sarcomas, adrenocortical tumors and liver malignancies. These cell isolates will be used for gene expression array analysis, genomic analysis by [SNP] single nucleotide polymorphism chip, array [CGH] comparative genomic hybridization and next generation sequencing, and [TEM] transmission electron microscopy analysis. Additionally cell lines and orthotopic xenografts will be created from the obtained tumor specimens.
The specificity of TCRs will be examined by comparing paired TCR from peripheral blood and tumor infiltrating CD4+ and CD8+ T cells. Epigenetic studies will be performed looking at the methylation profile of these cells and to investigate the anti-tumor T cell response both pre- and post-PD1 inhibition.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Each year approximately 2,200 children in the United States are diagnosed with neuroblastoma, osteosarcoma, Ewing sarcoma family of tumors (ESFT), retinoblastoma, soft tissue sarcomas, adrenocortical tumors and liver malignancies. These aggressive pediatric solid tumors are developmental tumors that initiate during periods of tissue growth and morphogenesis in the neural crest, bone and soft tissues. The overall survival rate of these tumors in the advanced stage is less than 30%. Despite intensive efforts over the past three decades using multiple therapeutic modalities including chemotherapy, surgery, radiation, autologous bone marrow transplant and biological agents there has been modest improvement in the long-term survival of these advanced stage pediatric solid tumors. A better understanding of the molecular, cellular and genetic changes that occur in the developing tissues as tumors form could improve the treatment of these devastating cancers. In particular, chemotherapeutic agents may be more effectively targeted to key regulatory enzymes or proteins if the study had a better understanding of the pathways that are disrupted as cells progress from preneoplastic lesions to metastatic disease. The specific aim of this proposal is to identify the changes in gene expression that occur in neuroblastoma, retinoblastoma, osteosarcoma, Ewing sarcoma family of tumors [ESFT] and soft tissue sarcoma cells and to correlate these changes with genetic and cellular changes in the tumor cells. [RNA] ribonucleic acid and genomic [DNA] deoxyribonucleic acid will be isolated from neuroblastoma, retinoblastoma, osteosarcoma, ESFT [Ewing sarcoma family of tumors] and soft tissue sarcomas (both primary and metastatic lesions) following surgery or bone marrow aspiration of previously untreated patients. Additional testing will be conducted on tumor samples at any point during or following therapy in which a surgical specimen is obtained. When there is sufficient tumor sample remaining after pathological analysis and banking, fresh primary tumor cells will be used to prepare orthotopic xenografts and to establish models of each disease that recapitulate the advanced forms of neuroblastoma, osteosarcoma, Ewing sarcoma family of tumors [ESFT], retinoblastoma and soft tissue sarcomas. For a small group of these excess samples, this study will perform fixation for electron microscopy and process the samples for [TEM] transmission electron microscopy analysis. These studies will complement our active research program characterizing the molecular, cellular and genetic features of genetically engineered mouse models of each of these diseases. Biological samples from the cohort of patients treated at St. Jude Children's Research Hospital will be complemented with samples collected and processed by collaborating institutions around the world. Samples collected from international collaborators will be used for analysis of [DNA] deoxyribonucleic acid and [RNA] ribonucleic acid to complement the St. Jude Children's Research Hospital cohort. Through this collaboration the study anticipates that they will be able to obtain enough fresh tumor samples to improve their understanding of multistage tumorigenesis in pediatric solid malignancies.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Sara M. Federico, MD
- Telefonnummer: 1-866-278-5833
- E-mail: referralinfo@stjude.org
Studiesteder
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- Rekruttering
- St. Jude Children's Research Hospital
-
Kontakt:
- Sara M. Federico, MD
- Telefonnummer: 866-278-5833
- E-mail: referralinfo@stjude.org
-
Ledende efterforsker:
- Sara M. Federico, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients identified at St. Jude Children's Research Hospital and collaborating institutions with a suspected or known diagnosis of neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma or soft tissue sarcoma based initial diagnostic workup and evidence of gross disease amenable to excision.
Beskrivelse
Inclusion Criteria:
- Must have a suspected or known diagnosis of neuroblastoma, osteosarcoma, Ewing sarcoma family of tumor or soft tissue sarcoma based on the initial diagnostic workup and evidence of gross disease amenable to excision. Specimens may be collected at some or all of the following time points: initial biopsy, bone marrow aspiration procedures, tumor resection, and at time of possible relapse.
- Patients with a diagnosis of retinoblastoma based on initial diagnostic workup and who require enucleation may be enrolled if there is no active therapeutic or biologic protocol for retinoblastoma.
- The patient or his/her legal guardian, as appropriate, must provide written informed consent within 30 days of the removal of the first collection of tissue/bone marrow/blood sample for this protocol.
- The patient is being seen at St. Jude Children's Research Hospital or at a collaborating institution.
- Patients must be less than or equal to 25 years old at the time of enrollment.
Exclusion Criteria:
- Patient is known to be Hepatitis B, Hepatitis C and/or HIV positive.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Udfør analyse af genekspressionsprofiler. [RNA]-ribonukleinsyre vil blive isoleret fra frisk frosne tumorprøver og hybridiseret til Affymetrix-genekspressionsarrays.
Tidsramme: 5 år
|
5 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Udfør analyse af store kromosomale ændringer såsom amplifikationer og deletioner. [DNA] deoxyribonukleinsyre isoleret fra tumoren og blodprøver vil blive hybridiseret til array [CGH] komparative genomiske hybridiseringschips.
Tidsramme: 5 år
|
5 år
|
|
Udfør analyse af fokale ændringer i genomet, herunder amplifikation, deletion og tab af heterozygositet (LOH). DNA isoleret fra tumoren og blodprøver vil blive hybridiseret til [SNP] single nucleotid polymorphism chips.
Tidsramme: 5 år
|
5 år
|
|
Udfør analyse af punktmutationer. DNA isoleret fra tumoren og blodprøver vil blive sekventeret ved hjælp af næste generations sekventeringsteknologi for at bestemme sekvensen af hele genomet.
Tidsramme: 5 år
|
5 år
|
|
Udfør analyse af cellemorfologi. Vævsprøver vil blive fikseret i en buffer, der er egnet til transmissionselektronmikroskopi og behandlet til [TEM] transmissionselektronmikroskopianalyse.
Tidsramme: 5 år
|
5 år
|
|
Sammenlign mikro-RNA'er i tumorer. Mikro-RNA'er vil blive isoleret fra den totale [RNA]-ribonukleinsyre, der er tilbage fra genekspressionsanalysen beskrevet ovenfor. Disse prøver vil blive brugt til mikro [RNA] chipanalyse eller dyb sekventering.
Tidsramme: 5 år
|
5 år
|
|
Sammenlign epigenetiske modifikationer af [DNA] deoxyribonukleinsyre. Genomisk DNA vil blive isoleret, og DNA-methylering vil blive analyseret på tværs af genomet for at bestemme, om denne epigenetiske proces er ændret i tumorprøverne.
Tidsramme: 5 år
|
5 år
|
|
Sammenlign epigenetiske modifikationer af kromatin. Celler vil blive hurtigt fikseret, og kromatin vil blive fremstillet for direkte at probe protein-DNA-komplekser ved [ChIP-seq]chromatin immunopræcipitation eller [ChIP-chip analyse] kromatin immunopræcipitation
Tidsramme: 5 år
|
5 år
|
|
Udfør proteinanalyse. Tumorceller vil hurtigt blive frosset til efterfølgende isolering af totalt protein eller specifik fraktion af cellulære proteiner (dvs. nukleare, cytoplasmatiske, membranproteiner).
Tidsramme: 5 år
|
5 år
|
|
Udfør immunhistokemisk og FISH-analyse af neuroblastom, osteosarkom, retinoblastom, ESFT og bløddelssarkomer. Vævsmikroarrays vil blive fremstillet ud fra prøver indsamlet i denne undersøgelse.
Tidsramme: 5 år
|
5 år
|
|
Celleisolater opnået fra primære og metastatiske tumorprøver vil blive brugt til at etablere cellelinjer og ortotopiske xenografter i immunkompromitterede mus.
Tidsramme: 5 år
|
5 år
|
|
Udfør analyse af cellevækst, metastaser og følsomhed over for kemoterapi.
Tidsramme: 5 år
|
5 år
|
|
Evaluer omfanget af immuncelleinfiltration og deres funktionelle status i pædiatriske solide tumorer ved hjælp af flowcytometrisk analyse af friske tumorprøver.
Tidsramme: 5 år
|
5 år
|
|
Evaluer tumorassocierede makrofager (TAMS'er) efter terapi for at lokalisere genekspressionsmønstre, markører og funktionelle korrelater af makrofagers vævsreparationsegenskaber i post-terapi mikromiljøet.
Tidsramme: 5 år
|
5 år
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Sara M. Federico, MD, St. Jude Children's Research Hospital
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Øjensygdomme
- Neoplasmer, kirtel og epitel
- Øjensygdomme, arvelig
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neoplasmer, bindevæv og blødt væv
- Neuroektodermale tumorer, primitive, perifere
- Neuroektodermale tumorer, primitive
- Neoplasmer, Knoglevæv
- Neoplasmer, bindevæv
- Neoplasmer, muskelvæv
- Myosarkom
- Øjeneoplasmer
- Nethindesygdomme
- Retinale neoplasmer
- Neuroblastom
- Sarkom, Ewing
- Sarkom
- Rhabdomyosarkom
- Osteosarkom
- Retinoblastom
Andre undersøgelses-id-numre
- MAST
- DOD-W81XWH-14-1-0103(CA130396) (Andet bevillings-/finansieringsnummer: DOD-Department of the Army)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .